
Please try another search
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ®¯platform to develop drug-Fc conjugate (DFC)...
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC)...
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC)...
SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC)...
Data highlights potential of CD388 as a potent, universal antiviral for influenza prevention regardless of immune status SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc....
Shane Ward, the Chief Operating Officer and Chief Legal Officer of Cidara Therapeutics, Inc. (NASDAQ:CDTX), recently executed a sale of common stock. According to a Form 4 filing with the Securities...
SAN DIEGO—Tari Leslie, the Chief Scientific Officer of Cidara Therapeutics, Inc. (NASDAQ:CDTX), reported a sale of company stock according to a recent SEC filing. On March 11, Leslie sold 1,773...
On Wednesday, Citizens JMP initiated coverage on Cidara Therapeutics (NASDAQ:CDTX), currently trading at $21 with a market capitalization of $230 million, assigning a Market Outperform rating and...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review